Medicilon(SH:688202) Zheng Quan Zhi Xing·2025-09-04 16:21Core Points - The announcement details a change in shareholder equity for Shanghai Medicy Bio-Pharmaceutical Co., Ltd, specifically a reduction in shareholding by major shareholder Lin Changqing [1][2] - Lin Changqing has reduced his shareholding from 5,473,654 shares (4.07%) to 4,523,654 shares (3.37%), resulting in a total reduction of 950,000 shares (0.71%) [1][2] - The combined shareholding of Lin Changqing and his associate Chen Guoxing decreased from 10,348,808 shares (7.70%) to 9,398,808 shares (7.00%) [1][2] Shareholder Information - Lin Changqing is the primary shareholder involved in the equity change, while Chen Guoxing remains unchanged with 487,515.4 shares (3.63%) [2] - The equity change does not trigger mandatory tender offer obligations and will not affect the company's controlling shareholder or actual controller [2] Additional Notes - The equity change is part of a previously disclosed share reduction plan, which is still in progress as of the announcement date [2] - The company will continue to comply with relevant regulations and fulfill its information disclosure obligations [2][3]